Načítá se...
Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction
A 62-year-old female patient with renal dysfunction and pulmonary adenocarcinoma developed postoperative recurrence and received carboplatin/pemetrexed and maintenance pemetrexed. As an anaplastic lymphoma kinase (ALK) gene translocation was identified, the therapy was changed to crizotinib. However...
Uloženo v:
Vydáno v: | Onco Targets Ther |
---|---|
Hlavní autoři: | , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
Dove Medical Press
2017
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499859/ https://ncbi.nlm.nih.gov/pubmed/28721071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S136837 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|